TABLE 2.
Results of autoimmune screening panel.
| Screening parameter | n total | n positive | % positive |
|---|---|---|---|
| ASL | 162 | 32 | 19.75 |
| C3c and C4 abnormal a | 134 | 31 a | 23.13 |
| C3c decreased | 134 | 26 | 19.40 |
| C3c increased | 134 | 1 | 0.75 |
| C4 decreased | 134 | 3 | 2.24 |
| C4 increased | 134 | 3 | 2.24 |
| RF | 180 | 0 | 0.00 |
| ANA total | 210 | 24 | 11.43 |
| ANA mild | 210 | 18 | 8.57 |
| ANA moderate | 210 | 5 | 2.38 |
| ANA strong | 210 | 1 | 0.48 |
| Anti‐dsDNA total | 208 | 2 | 0.96 |
| dsDNA borderline | 208 | 1 | 0.48 |
| dsDNA definite | 208 | 1 | 0.48 |
| ENA total b | 211 | 10 b | 4.74 |
| SSA/antiRo total | 211 | 6 | 2.84 |
| SSA/antiRo borderline | 211 | 1 | 0.47 |
| SSA/antiRo definite | 211 | 5 | 2.37 |
| SSB/antiLa total | 211 | 2 | 0.95 |
| SSB/antiLa borderline | 211 | 1 | 0.47 |
| SSB/antiLa definite | 211 | 1 | 0.47 |
| SM total/borderline | 211 | 3 | 1.42 |
| Centromere B | 211 | 2 | 0.95 |
| u1RNP | 211 | 0 | 0.00 |
| SCL‐70 | 211 | 0 | 0.00 |
| Jo‐1 | 211 | 0 | 0.00 |
| Cardiolipin IgM | 205 | 4 | 1.95 |
| Cardiolipin IgG | 204 | 0 | 0.00 |
| SMA | 167 | 11 | 6.59 |
| ß2GP IgM, total/borderline | 203 | 5 | 2.46 |
| ß2GP IgG | 204 | 0 | 0.00 |
| cANCA | 205 | 0 | 0.00 |
| pANCA | 205 | 0 | 0.00 |
| Antimitochondrial | 173 | 0 | 0.00 |
Abbreviations: ANA, antinuclear antibody; anti‐dsDNA, anti‐double‐stranded DNA antibody; ASL, antistreptolysin; cANCA, cytoplasmic antineutrophil cytoplasmic antibody, ENA, extractable nuclear antigen; Jo‐1, myositis specific antibody; pANCA, perinuclear antineutrophil cytoplasmic antibody; RF, rheumatoid factor; SCL‐70, anti‐topoisomerase I; SM, Smith antibody; SMA, smooth muscle cell antibody; ß2GP, beta‐2 glycoprotein; SSA/antiRo and SSB/antiLa, anti‐Sjögren syndrome‐related antigen A/B; u1RNP, u1‐ribonucleoprotein.
a
Two patients had decreased levels of both C3c and C4.
b
Three patients were positive for multiple ENAs.